Stock Financial Ratios and Split History

CFCOU / CF Corporation, Units financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,317.34
Enterprise Value ($M)1,409.34
Book Value ($M)1,952.00
Book Value / Share9.11
Price / Book181.61
NCAV ($M)-27,977.00
NCAV / Share-130.51
Price / NCAV-0.08
Income Statement (mra) ($M)
Net Income0.00
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio
Current Ratio
Share Statistics
Common Stock Shares Outstanding214,370,000
Weighted Average Number Of Shares Outstanding Basic58,320,000
Weighted Average Number Of Diluted Shares Outstanding58,415,000
Common Shares Outstanding214,370,000
Preferred Stock Shares Outstanding375,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.00
Identifiers and Descriptors
Central Index Key (CIK)1668428
Industry Groups

Split History

Stock splits are used by company's to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can issue all shareholders an extra share, thereby halving the price. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted

Coming soon

Peers -

Related News Stories

CF Industries Holdings' (CF) CEO Anthony Will on Q4 2017 Results - Earnings Call Transcript

2018-02-15 seekingalpha
CF Industries Holdings, Inc. (NYSE:CF) Q4 2017 Earnings Conference Call February 15, 2018 9:00 AM ET (33-0)

Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

2018-02-13 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) announced that the FDA has granted approval to its cystic fibrosis (CF) corrector, tezacaftor (VX-661), in combination with ivacaftor (Kalydeco) under the brand name, Symdekotm. The combo therapy is approved to treat the underlying cause of CF in patients aged 12 years and above with certain mutations in the CF transmembrane conductance regulator gene. (52-0)

Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

2018-01-25 zacks
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) shares are up 70.1% in the past year, comparing favorably with an increase of 9.6% for the industry. (82-0)

BRIEF-CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​

2017-11-20 reuters
* CF corp - ‍CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​ Source text for Eikon: Further company coverage: (16-1)

Vertex Gets CHMP Recommendation for Orkambi Label Expansion

2017-11-13 zacks
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the Committee for Medicinal Products for Human Use ("CHMP") has recommended approval of a label expansion for Orkambi in Europe. The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis ("CF") who are aged between 6 and 11 years and have two copies of the F508del mutation. (63-1)

CUSIP: G20307123